Lycia Therapeutics IPO: $938M Valuation, $265M Raise, and the LYTAC Pipeline Behind Ticker LYCA

Lycia Therapeutics set terms for a Nasdaq IPO on October 20, 2026 — 14.7 million shares at $16 to $18, implying up to $937.7 million in valuation and $264.6 million raised, under ticker LYCA, according to a report carried by 979 WEVE. The deal hasn't priced yet.

Lycia Therapeutics IPO: The Terms So Far

Lycia Therapeutics set terms for its Nasdaq IPO on October 20, 2026: 14.7 million shares priced at $16.00 to $18.00 apiece, implying up to $264.6 million in proceeds and a valuation of up to $937.7 million at the top of the range. Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities are the joint book-running managers on the deal, which Value Add VC's Pulse coverage flagged as the latest entrant in an increasingly crowded fall biotech IPO window.

Lycia's filing lands a week after two other biotechs actually started trading: City Therapeutics and Iambic Therapeutics both went public in New York, and two more names — Aspen Neuroscience and Bambusa Therapeutics — filed their own US IPO registrations earlier in October. The deal is a traditional underwritten S-1 offering, not a reverse merger, so Lycia's final price is still subject to bookbuilding and could land anywhere in — or outside — the $16-$18 range.

Who's Behind Lycia Therapeutics

Versant Ventures founded Lycia Therapeutics in 2019 inside its San Diego-based Inception Sciences discovery engine, working with academic co-founder Carolyn Bertozzi, a Stanford chemistry professor who won the 2022 Nobel Prize in Chemistry for click chemistry and bioorthogonal chemistry. Lycia exited stealth in June 2020 with a $50 million commitment from Versant, according to the launch announcement.

Redmile Group led a $70 million Series B in September 2021, bringing in Eli Lilly, Invus, RTW Investments, and Alexandria Venture Investments alongside Versant. Venrock Healthcare Capital Partners then led an oversubscribed $106.6 million Series C in May 2024, adding Janus Henderson Investors, Marshall Wace, and Franklin Templeton to a syndicate that also included Blue Owl's healthcare opportunities arm (formerly Cowen Healthcare Investments), per Drug Development & Delivery's coverage of the round. Reuters' tally of roughly $266.6 million raised since Lycia's 2019 founding runs somewhat higher than the $226.6 million disclosed across these three named rounds, a gap that likely reflects additional, undisclosed capital — including Eli Lilly's upfront collaboration payment — rather than a round this piece has missed.

What's in the Pipeline

Lycia's platform is built on LYTACs — lysosomal targeting chimeras — synthetic molecules that drag disease-causing proteins outside and on the surface of cells into the lysosome for destruction, extending targeted protein degradation beyond the inside-the-cell mechanisms (like PROTACs) that dominate the field. The company is developing drugs for autoimmune, inflammatory, and allergic diseases on that platform, and its most advanced program, LCA-0061, is still in an early-stage clinical trial for food allergy — the IPO prices years of clinical risk before any pivotal readout, the same risk profile that has defined 2026's otherwise-thin biotech IPO pipeline.

Lycia's 2021 strategic collaboration with Eli Lilly, focused on immunology and pain, brought a $35 million upfront payment and remains active alongside the company's internal discovery pipeline, according to the Series B announcement.

How we counted: the seven most recent biotech IPO terms sheets, pricings, and filings on the US calendar as of October 20, 2026; deal size and dates as reported by each company's filing, terms sheet, or (for Aspen Neuroscience and Bambusa Therapeutics, which have not yet set price terms) Renaissance Capital's IPO calendar. Sources: 979 WEVE/Reuters, Renaissance Capital's Aspen Neuroscience and Bambusa Therapeutics filing coverage, and our own reporting on ADARx, TRexBio, Iambic Therapeutics, and City Therapeutics, checked October 20, 2026.

What the headline misses

Every figure here is a filing-stage estimate, not a closed deal. Lycia's own terms sheet gives a price range, not a final price, and the $937.7 million valuation and $264.6 million raise are both the top of that range — the deal could price below, at, or above $16-$18 once bookbuilding finishes, and biotech IPOs in 2026 have done all three.

The business itself is still purely pipeline-stage. LCA-0061 is only in an early-stage trial for food allergy, and the company has not disclosed any approved product or product revenue in the sources reviewed for this piece. Public investors in this IPO are pricing a protein-degradation platform and an early clinical program, not disclosed commercial revenue.

The funding totals also don't fully reconcile: Reuters' reported $266.6 million raised since 2019 is about $40 million higher than the sum of Lycia's three named, dated rounds ($226.6 million). That gap likely reflects Eli Lilly's upfront collaboration payment or other undisclosed capital rather than a missing financing round, but neither this piece nor the public record pins down the exact source of the difference.

Why This IPO Matters Beyond Lycia Therapeutics

Lycia is now the fifth biotech to set or price US IPO terms in roughly three weeks, following ADARx, TRexBio, Iambic Therapeutics, and City Therapeutics — with Aspen Neuroscience and Bambusa Therapeutics already filed behind it. Renaissance Capital's Matt Kennedy told Reuters that recent filings suggest Q4 2026 will bring more deals, with smaller and mid-cap names potentially becoming the window's future leaders, as healthcare anchors an otherwise subdued fall IPO market while investors stay selective amid higher interest rates. Whether that appetite holds depends on how Lycia and the two still-unpriced filings behind it actually price — not merely on banks' continued willingness to set terms.